Navigation Links
Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
Date:9/11/2008

Launch Scheduled for November 2008

CHENGDU, China, Sept. 11 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (OTC Bulletin Board: TYNP), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company has received approval from the Chinese State Food and Drug Administration (SFDA) to produce Laonian Kechuan Tablets in the dosage form of 0.25 gram/tablet (SFDA approval number Z20083360). The Company plans to launch Laonian Kechuan Tablets in the domestic market and begin recording revenue in November 2008.

Laonian Kechuan Tablets is a TCM drug that effectively treats asthma in people aged 60 or above. According to Chinese SFDA statistics, the market size in China for asthma drugs exceeded $580 million in 2004. Due to the low toxicity and high efficacy, TCM's for asthma have proven to be more readily accepted by patients, and currently comprise over 75% share of the retail market segment for long-term asthma drug users.

The fifth national census reveals that the population 60 years of age and older in China is about 144 million, accounting for one fifth of the world's total. According to China's epidemiology survey, the asthma incident rate among those 60 or above is close to 2.6%. The clinical trials showed that Tianyin's Laonian Kechuan Tablets can effectively boost immunity and improve the recovery of elder patients with asthma. The drug is also effective in treating chronic bronchitis and related indications such as physical weakness.

"We are very pleased to announce the approval of Laonian Kechuan Tablets from the Chinese SFDA, another milestone of our portfolio development which currently includes 37 drugs addressing a number of popular indications," Dr. Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc., commented. "The recent new drug approvals we have received confirm our ability of getting drugs through the
'/>"/>

SOURCE Tianyin Pharmaceutical, Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
9. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... 22, 2014 Although there are only 24 hours ... many people who have trouble finding time within their busy schedules ... for long periods of time to get in shape. Here are ... on the go. , Change Up Your Commute , Consider ... to add some exercise into your daily routine. If you must ...
(Date:10/22/2014)... 22, 2014 Richard Carlson, Managing Partner ... leader with over 25 years experience. Mr. Carlson ... the areas related to EDI, B2B Commerce, RFID and ... Editorial Advisory Board member for Pharmaceutical Commerce Magazine and ... Fin Group is a management and technology consulting firm ...
(Date:10/22/2014)... Reinberg HealthDay Reporter , TUESDAY, ... weight and length may be showing a genetic propensity for ... certain genes have been linked to increased body fat, but ... and lean muscle, the researchers said. At 1 year, ... ages 2 and 3, however, these genes were linked to ...
(Date:10/22/2014)... 2014 (HealthDay News) -- Two sisters in high school ... Ilina and Medha Krishen use electronic stethoscopes, which ... trouble in breathing patterns or heartbeats. Ilina, a ... wanted to find a way to detect early lung ... an electronic stethoscope, Ilina recorded one breath cycle each ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... Feb. 10 SilverCensus.com Inc. ( http://www.silvercensus.com ), ... healthcare professionals, announced today its expansion to a ... a Foundation that aims to revolutionize the way ... are a comprehensive senior living and senior healthcare ...
... Myeloma and Bone Cancer Research (IMBCR) have uncovered a ... within tumors.LOS ANGELES, Feb. 10 IMBCR researchers uncovered ... their own blood supply. Recent studies have shown that ... now show that PTN produced by tumor cells in ...
... AVC-Intra encoding, 64-bit support, seamless integration and improved quality ... MainConcept GmbH, a wholly-owned subsidiary of DivX, Inc. ... world,s leading providers of video/audio codecs and software development ... today announced the release of Codec SDK 8.0 with ...
... Technique Breast-Specific Gamma Imaging (BSGI) Resulting in Record ... Technologies, Inc., a leader in molecular breast imaging, ... the strongest fourth quarter in the company,s history. ... sales from 2007 to 2008 as molecular breast ...
... Feb. 10 Arete Therapeutics Inc. today,announced the initiation ... orally-,administered soluble epoxide hydrolase (s-EH) inhibitor being developed for,the ... involved in the metabolism,of arachidonic acid, a key signaling ... "Our AR9281 Phase II clinical trial ...
... Feb. 10 - Zeus, Inc. announces new product name changes that ... unaltered in composition and processing. They remain the same quality products ... , New brand names are as follows: , ... New trademarked product Aeos (TM), formerly known as ...
Cached Medicine News:Health News:SilverCensus.com Launches National Website for Caregivers, Senior Citizens, Healthcare Professionals 2Health News:Researchers Identify Novel Mechanism That Make Cancer Tumors Grow 2Health News:MainConcept Releases New Codec SDK 8.0 2Health News:MainConcept Releases New Codec SDK 8.0 3Health News:MainConcept Releases New Codec SDK 8.0 4Health News:Dilon Technologies Leads Molecular Breast Imaging Expansion 2Health News:Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes 2Health News:Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes 3Health News:Zeus Announces Product Name Changes 2
(Date:10/22/2014)... CITY, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced that results from the  IAP310 study ... Pain Medicine (RAPM), a peer-reviewed journal with ... Phase 3 trial evaluating the safety and efficacy ... sublingual tablet system (SSTS), for the treatment of ...
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( ... pulmonology, today announced completion of enrollment in their RENEW ... Clinical Study is the FDA-approved IDE pivotal trial for ... emphysema. It was anticipated that the study, ... 2013, would take until the end of 2014 to ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: